Greenlight Capital: Boston Scientific’s Out, Gold Still In

Market Folly submits:Dealbreaker has flagged David Einhorn and hedge fund Greenlight Capital’s first quarter investor letter. In it, we learn that the fund has exited its position in Boston Scientific (BSX). Readers will remember that Einhorn had just started this position and mentioned it in his fourth quarter investor letter. The hedge fund purchased shares of BSX for $8.42 and sold them for $7.57. So, Greenlight has cut its losses quickly on this one and moved on to the next investment.The Greenlight team writes,